PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 88 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $16,101,889 | +1.3% | 1,435,106 | 0.0% | 5.25% | -3.5% |
| Q3 2022 | $15,901,000 | +31.3% | 1,435,106 | 0.0% | 5.44% | +40.2% |
| Q2 2022 | $12,112,000 | -37.9% | 1,435,106 | 0.0% | 3.88% | -29.9% |
| Q1 2022 | $19,503,000 | -17.4% | 1,435,106 | +19.3% | 5.53% | -3.3% |
| Q4 2021 | $23,606,000 | -38.7% | 1,203,135 | 0.0% | 5.72% | -34.5% |
| Q3 2021 | $38,512,000 | -5.4% | 1,203,135 | 0.0% | 8.74% | -30.6% |
| Q2 2021 | $40,726,000 | -9.6% | 1,203,135 | 0.0% | 12.59% | -19.1% |
| Q1 2021 | $45,057,000 | +12.8% | 1,203,135 | 0.0% | 15.56% | +13.8% |
| Q4 2020 | $39,956,000 | -10.2% | 1,203,135 | 0.0% | 13.67% | +43.5% |
| Q3 2020 | $44,516,000 | +13.1% | 1,203,135 | 0.0% | 9.52% | -13.5% |
| Q2 2020 | $39,367,000 | +27.7% | 1,203,135 | 0.0% | 11.01% | -46.2% |
| Q1 2020 | $30,824,000 | -17.6% | 1,203,135 | 0.0% | 20.47% | +13.2% |
| Q4 2019 | $37,430,000 | – | 1,203,135 | – | 18.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 5,827,415 | $187,060,000 | 14.97% |
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $66,378,000 | 14.44% |
| Abingworth LLP | 1,203,135 | $38,512,000 | 8.74% |
| Penn Mutual Asset Management, LLC | 86,940 | $2,791,000 | 4.41% |
| GREAT POINT PARTNERS LLC | 220,863 | $7,090,000 | 1.65% |
| RA Capital Management | 3,115,008 | $99,992,000 | 1.39% |
| StepStone Group LP | 422,085 | $13,549,000 | 0.88% |
| Summit Rock Advisors, LP | 34,100 | $1,094,000 | 0.65% |
| Rhenman & Partners Asset Management AB | 186,210 | $5,977,000 | 0.42% |
| Eventide Asset Management | 600,000 | $19,260,000 | 0.25% |